chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Information has been received from a physician concerning a 21 year old female patient who on 07-OCT-2010 was vaccinated with a dose of PNEUMOVAX 23 (Lot#667418/0978Z), IM, into the right arm (Exp. Date Unspecified). Concomitant therapy included a dose of FLUZONE given into the patient's left arm and a dose of ADACEL given into the patient's left arm. It was reported that the patient experienced fever and had a red swollen elbow as a result of being in therapy with PNEUMOVAX 23. Subsequently, the patient recovered from all these symptoms. The patient sought medical attention at the physician's office. Follow up information has been received from the physician and the medical assistant who stated that the 21 year old female patient with asthma and no illness at the time of vaccination received the dose of PNEUMOVAX 23 (Lot#667418/0978Z), IM, into the left arm (also reported as right arm by the medical assistant). Concomitant vaccines given on the same day included a dose of ADACEL (Lot # C3491AA) and a dose of FLUZONE (Lot # U3639DA) both given IM into the left arm. The physician stated that after receiving the vaccine the patient developed a skin reaction in her left upper arm. The area had been red, swollen, warm and tender. Vital signs reported were: BP: 110/60, LUE. Sitting, HR: 76 b/min. Temp: 97.9 F, Tympanic. A physical exam showed: GEM: Comfortably conversing and ambulating. Good eye contact. No acute distress. Mental status intact. Well-nourished and developed. Skin: 4 cm circular erythematous, swollen, tender (with rebound and guarding) patch over left upper arm (ventral, mid-section) at side of PNEUMOVAX 23 injection. The physician reported that the patient's skin reaction was slowly improving. She was advised symptomatic relief with ice/heat, ibuprofen and TYLENOL q6hr/p.r.n. Follow up information has been received from the medical assistant via a telephone call. It was confirmed that the vaccine dose of PNEUMOVAX 23 was given in right arm on 07-OCT-2010. This is one of several reports received from the same source. No further information is available.
This case was reported by a consumer via out of hour services and described the occurrence of chills in a 76-year-old male patient who received SHINGRIX. On 16th May 2018, the patient received the 2nd dose of SHINGRIX (intramuscular) .5 ml. On 17th May 2018, 1 days after receiving SHINGRIX, the patient experienced chills, fever, malaise, weakness, foggy feeling in head, forgetfulness, memory loss, fatigue, tremor and influenza-like symptoms. On 17th May 2018, the outcome of the chills, fever, malaise, foggy feeling in head, forgetfulness, memory loss, tremor and influenza-like symptoms were recovered/resolved. On an unknown date, the outcome of the weakness and fatigue were not recovered/not resolved. The reporter considered the chills, fever, malaise, weakness, foggy feeling in head, forgetfulness, memory loss, fatigue, tremor and influenza-like symptoms to be related to SHINGRIX. Additional details were reported as follows: This case was previously reported to a doctor. At 17:00 patient received SHINGRIX on left deltoid. The morning of 17th May 2018, the patient experienced chills, shaking, fever, malaise, memory loss, flu like symptoms, followed by significant brain fog and forgetting the names of common household objects. On the day of reporting, all of the symptoms had resolved except he was weak and felt fatigued. The reporter initially reported the adverse event on the after hours voicemail line. The reporter's husband got on the telephone and gave permission for his physician to be contacted.
Treatment of COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 57-year-old female patient (not pregnant) received bnt162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), on 06Nov2023 at 16:00 as dose 1, single (Lot number: HG4671), in left arm for covid-19 immunisation; for covid-19 immunisation. The patient's relevant medical history was not reported. Concomitant medication(s) included: ROSUVASTATIN, start date: 01May2023, stop date: 10Nov2023. Vaccination history included: Covid-19 vaccine (DOSE 1; MANUFACTURER UNKNOWN), for COVID-19 Immunization; Covid-19 vaccine (DOSE 2; MANUFACTURER UNKNOWN), for COVID-19 Immunization; Covid-19 vaccine (DOSE 3; MANUFACTURER UNKNOWN), for COVID-19 Immunization; Covid-19 vaccine (DOSE 4; MANUFACTURER UNKNOWN), for COVID-19 Immunization; Covid-19 vaccine (DOSE 5; MANUFACTURER UNKNOWN), for COVID-19 Immunization. The following information was reported: COVID-19 (non-serious) with onset 10Nov2023, outcome "unknown", described as "Treatment of COVID-19". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of covid-19.  Additional information: Patient received Paxlovid on 10Nov2023 until 15Nov2023.  The information on the batch/lot number for bnt162b2 omi xbb.1.5  has been requested and will be submitted if and when received.
1020 Mother reported the patient feeling dizzy. Went to go get juice for the patient. Patient was then reported to be lightheaded. Mother requested Benadryl and an EPI-pen.  Pt stated she was hot and cold and nauseous. Patient was pale in color.  Patient was laid down with feet elevated.  Cooling measures applied. Vitals checked.  1024 Blood sugar: 105 BP 110/67 HR 80 R 24 O2 Sat 99 %.   Patient was encouraged to take slow deep breathes,   1030 BP 115/75 HR 70 R 20 O2 Sat 99%.  Patient was provided water, juice and a protein bar.  Patient was able to be sat up in the sitting position and was feeling better. Encouraged fluids for patient.  Patient stated she had not eaten or drank much prior to appointment.  1052 patient left with mother and brother. Color had came back, patient stated she felt better. Mom advised they were headed to get lunch.
This is the reporting of a vaccination error and not an adverse event that occurred.  Situation: Patient was administered the Fluad Quadrivalent flu vaccine on 11/02/2022, but he had already received the same Fluad Quadrivalent flu vaccine earlier on 10/27/2022.  As the patient received two doses of Fluad Quadrivalent flu vaccine within the same 2022-2023 flu season in error, what are the possible risks/side effects should we look out for? Since patient also received several other vaccines (Shingrix, Pneumovax 23) within one week prior to receiving the second dose of Fluad Quadrivalent flu vaccine, would this second dose of flu vaccine interact with the efficacy of those vaccines, and/or result in greater risk of adverse events?
Received HPV, walking to waiting chair while twin was preparing to get shot. Child observed to fall forward, hitting head on desk. LOC noted. EMS activated. Awake and alert upon medic arrival. DC home with parent. Twin did not receive HPV.
This patient received her 2nd Moderna vaccine last week, w 10 days ago. She was seen in the ED today Submassive PE.
Headache, significant aches, sharp pain in lymph nodes under arm and rib cage in side in which shot was given
This case was reported by a consumer via call center representative and described the occurrence of tinnitus aggravated in a male patient who received FLUARIX Quadrivalent. Concurrent medical conditions included tinnitus and hearing impaired. On 13th August 2016, the patient received FLUARIX Quadrivalent. The patient experienced tinnitus aggravated, hearing decreased and condition aggravated. On an unknown date, the outcome of the tinnitus aggravated hearing decreased and condition aggravated were not recovered/not resolved. It was unknown if the reporter considered the tinnitus aggravated to be related to FLUARIX Quadrivalent. The reporter considered the hearing decreased and condition aggravated to be possibly related to FLUARIX Quadrivalent. Additional details were provided as follow: The patient received a dose of FLUARIX Quadrivalent at his local pharmacy. The patient did not have lot  numbers nor any other information on the vaccine. Right away, like a few hours after vaccination, the patient started noticing that his tinnitus has increased and his hearing decreased substantially. The patient did not recovered from the events. The patient thought it might be due to the medication. The patient did not want to provide any details regarding demographics, not even initials. The patient was given a reference number and was asked to call back with that reference number if he gets any further information.
8 cm diameter area of redness and tenderness around vaccine site. Some induration present. No abscess palpable or visible. No groin adenopathy. This occurred about one week after the shot. Given Rx for antibiotic.
pneumonia; bronchitis; wracking cough; Initial information received on 11-Nov-2020 regarding an unsolicited valid serious case received from a consumer or non-healthcare professional via social media.  This case involves patient (unknown demographics) who experienced pneumonia, bronchitis and wracking cough (cough), while he/she received vaccine INFLUENZA VACCINE.  The patient's medical history, past medical treatment, vaccination, concomitant medication and family history were not provided.   On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE (produced by unknown manufacturer, lot number not reported) via an unknown route at an unknown administration site for prophylactic vaccination.  On an unknown date, the patient developed a serious event pneumonia unknown latency following the administration of INFLUENZA VACCINE. This event was assessed as medically significant.  On an unknown date, the patient developed non-serious events bronchitis and wracking cough (cough) unknown latency following the administration of INFLUENZA VACCINE.  Laboratory details were not reported.   It was not reported if the patient received a corrective treatment.  The event outcome was unknown for all events.  Information on batch number was requested.; Sender's Comments: This poorly documented social media case concerns a patient (unknown demographics) who suffered from pneumonia, bronchitis and cough after vaccination with INFLUENZA VACCINE (produced by unknown manufacturer). The time to onset was unknown. Moreover, patient's medical condition at the time of vaccination, lab tests ruling out predisposing etiologies were not reported. Based upon the reported information and considering the infectious nature of the event, the role of the vaccine cannot be assessed.
Information has been received from a health professional concerning a 4 year old patient who was vaccinated with a dose of varicella virus vaccine live (Oka/Merck). On 02-Apr-2007, the patient was diagnosed with chickenpox. Medical attention was sought. The patient's outcome was unknown. No product quality complaint was involved. This is one of several from the same source. Additional information is expected.
Fever of 101.3, bad headache, fatigue, mild cough.  I passed out briefly the morning after due to the fever and fatigue.
patient was administered the second dose of the Moderna Covid 19 Vaccine two weeks early. Patient was monitored 15 mins post vaccine administration and displayed no adverse symptoms. Patient contacted by provider on May 13 and patient continued to deny having fever body aches or congestion.
devel red raise pinpoint rash @ inj site & enlarged on thighs;both legs;
Localized reaction. site red, hot, swollen, "hard to touch' Duration-5 days Temp 99.0- Tx with Tylenol Resolved
shingles; Information has been received from a lawyer regarding a case in litigation concerning a unknown age female patient. The patient's historical condition, concomitant medications and drug reactions or allergies were not reported.  On an unspecified date in 2013, the patient was vaccinated with zoster vaccine live(ZOSTAVAX)(strength, dose, frequency, route, lot # and expiration date were not reported) for the long-term prevention of shingles and zoster-related condition.  On an unknown date, the patient was treated for shingles. The event caused the patient hospitalization. As a direct and proximate result of Plaintiff's use of zoster vaccine live(ZOSTAVAX) vaccine, Plaintiff has and would continue suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies;diminished capacity for the enjoyment of life; diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; and other losses and damages; and will continue to suffer such losses, and damages in the future. The outcome of event was unknown. The reporter considered herpes zoster to be related to Zoster Vaccine Live(ZOSTAVAX).
About an hour after the injection came a sore throat, followed by a congested sinus and runny nose a few hours later. The sore throat faded away after a full day, and the runny nose after 3 days. Sinus is slightly less congested, and headache and dizziness are currently being experienced.
It was brought to me attn. on Friday, 2/17/17, in the afternoon, by my Medical Support supervisor, that I had "...documented a 3+ flu for this 2 yr old child." I was at a different clinic that day so was unable to research this incident until I returned to my normal clinic on 2/20/17. I replied to my MSS on Monday, 2/20/17, stating I had documented the vaccine correctly but had given the patient the incorrect flu vaccination. He instructed me to follow the "Procedure: Immunization Accuracy". I called the CDC on 2/20/17 at 3:45pm, however, they were closed for holiday. I called the CDC again on 2/21/17 at 9:45am and reported the above incident to employer at CDC. Employee stated that the side effect of giving the older child flu shot to this younger patient would have been increased redness or skin reaction around the area the shot was given. The patient should still get the 2nd dose of flu vaccine like normal if they return to the clinic. Employee asked if the parent called us to notify us of any issues with this vaccination, and I told her no. She said it is recommended to call the Health Dept for further recommendations. I called Health Dept. She started I need to s/w their nurse so she transferred me to the nurse on duty. I had to leave a vm for the nurse to call us back. I forwarded this patient case to the patient's PCP to review today.
Information has been received from a physician concerning two patients who were vaccinated with a dose of GARDASIL vaccine (lot not reported) and fainted after receiving the vaccine. Additional information has been requested. This is in follow-up to report (s) previously submitted on 8/14/2008. Follow-up information was received on 04-SEP-2008 from the physician indicating that the physician had had several girls fainted with GARDASIL vaccine. The physician had not otherwise make any reports. Additional information is not expected.
Experienced severe shortness of breath 2 hours after her flu shot. She also has a fever today with flu like symptoms.
5 min after receiving Hep A #2 while seated on exam table with tourniquet on arm looking for vein to draw blood. Pt slumped over, then hit (L) side of head on wall, both arms were tonic & (R) leg was shaking. Event lasted 30 sec.
11 days post vaccination - injection site is raised, red, warm to touch, and itches.
I have an underlying autoimmune condition that I feel worsened the side effects I experienced. I have Postural Orthostatic Tachycardia Syndrome that causes me to faint, and other dysautonomia symptoms that could be considered a cluster or syndrome, like bladder spasms and blood pressure drops, etc, all related to autonomic nervous system issues. My symptoms are now rare and mostly under control. I had sudden onset of POTS 12/24/2006, it was incredibly severe until late 2008, then slowly got better over the next 5 years. I now live a 90% normal life.  The second dose of the pfizer vaccine notably worsened all my autonomic symptoms, causing most of them to return for approximately 1 month after getting the second dose. About 24 hrs after second dose I noticed my resting heart rate went up to 110 when my normal heart rate is about 80. I had episodes of sudden blood pressure drop when sitting up watching tv, my face would lose color and I would have to lie back flat to keep from fainting. I became very exhausted going up the stairs in my house. Symptoms stayed very bad for about 2 weeks. They improved slowly after that. It took about a month for my resting heart rate to return to normal, and to climb the stairs without becoming exhausted.
Twelve Moderna vaccines were given in office. Only 11 were drawn up this morning and the 12th dose was, most likely, a left over dose from yesterday. After incident was discovered, Moderna manufacturer was contacted per CDC recommendation. (Case #: MOD21-060693). Employee in Quality was also notified.  Communication to patient: The Moderna Vaccine you received may have been outside of the 6 hour thaw recommendation. We contacted the Moderna manufacturer and CDC. At this time, there are no recommendations for revaccination. You will still receive your 2nd dose as previously scheduled. Titers will be available at no cost in 2-3 months after your second vaccine.
Vertigo; Arm pain; Vomiting; Nausea; Fatigue; This spontaneous case was reported by a consumer and describes the occurrence of VERTIGO (Vertigo), VACCINATION SITE PAIN (Arm pain), VOMITING (Vomiting), NAUSEA (Nausea) and FATIGUE (Fatigue) in a 27-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 14-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Jan-2021, the patient experienced FATIGUE (Fatigue). On 15-Jan-2021, the patient experienced VERTIGO (Vertigo), VACCINATION SITE PAIN (Arm pain), VOMITING (Vomiting) and NAUSEA (Nausea). The patient was treated with HYDROCHLOROTHIAZIDE (MICROZIDE [HYDROCHLOROTHIAZIDE]) for Adverse event, at an unspecified dose and frequency. At the time of the report, VERTIGO (Vertigo), VACCINATION SITE PAIN (Arm pain), VOMITING (Vomiting), NAUSEA (Nausea) and FATIGUE (Fatigue) had resolved.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.       Consumer reported he visited an urgent care on unspecified date. He received unspecified medication to treat vertigo and nausea, and was instructed to hydrate.  Consumer visited his primary care physician on 19-Jan-2021 and was again treated with unspecified medication for vertigo.   Consumer reported the events fully recovered before receiving the second dose of the vaccine.   This case was linked to MOD-2021-237299.   Most recent FOLLOW-UP information incorporated above includes: On 25-Jun-2021: Follow-up received on 25-Jun-2021 included new information- patient's demographics, Events of first dose recovered prior to second dose. Additional treatment information.
Seizure treated with anti-seizure medications, antibiotics, and mechanical ventilation for airway support
gradual onset of blanching, non urticarial maculopapular rash on thighs and lower abdomen/lower back within 18 hours after vaccine given, started to slightly improve 2 days after but present. No other symptoms.
This case was reported by a other health professional via sales rep and described the occurrence of pain in a 64-year-old female patient who received SHINGRIX (batch number 7FY22, expiry date unknown). The patient's past medical history included diabetes. On 23rd April 2018, the patient received the 1st dose of SHINGRIX. On an unknown date, less than a month after receiving SHINGRIX, the patient experienced pain. On an unknown date, the outcome of the pain was unknown. It was unknown if the reporter considered the pain to be related to SHINGRIX. Additional information was reported as follows: This case was reported by a administrator. The patient had soreness for a period beyond 5 days. The reporter did not make any conclusion on the causality of the event the product. The reporter did not make any conclusion on the causality of the event and the product. It was not sure if the reporter agreed to follow up for this case.
Hives after 10km run.  0100 following morning fever, intense pain on injection arm.  Pain subsiding and fever subsubsiding a bit by 0300.  Headache, aches, fatigue till evening the following day.
received a half dose booster without completing a primary vaccination series; This spontaneous case was reported by a nurse and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (received a half dose booster without completing a primary vaccination series) in a 60-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Previously administered products included for Product used for unknown indication: JANSSEN COVID-19 VACCINE. Past adverse reactions to the above products included No adverse event with JANSSEN COVID-19 VACCINE. Concurrent medical conditions included Psychiatric disorder NOS.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (received a half dose booster without completing a primary vaccination series). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (received a half dose booster without completing a primary vaccination series) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications reported. No treatment information was provided. The facility thought that the patient never got the primary series. So the patient possibly received a half dose booster without completing a primary vaccination series.
On February 4th I had the worst sore throat I could ever recall and started to develop fatigue. The day before my entire household had taken COVID19 tests at home and they were negative. On the 5th we were still sick and took another test and we were all glaringly positive. The next day I contacted my doctor because I was having chills, cough, still sore throat and tired. They prescribed Paxlovid. The cough started to clear pretty quickly but the fatigue lasted through the end of the week. The sore throat started getting better the day after Paxlovid. I contacted my employment and was told I could probably go back on February 15th but I worked telehealth because I was still fatigued and dragging. I went back to campus on February 22nd and was completely symptom free at that point.